Therefore, the mode of cancer treatment can be more precisely known by drug sensitivity analysis, and our results showed that the potential of TTN, ARID1A, KDM6A, and RB1 as drug scanning targets for BLCA, indicating that the expression of TTN, ARID1A, KDM6Aand RB1 is positively associated with most drugs in CTRP (Figure 10A). The gene discussed is ARID1A; the disease is cancer.